Cargando…
Enzyme Redesign Guided by Cancer-Derived IDH1 Mutations
Mutations in an enzyme can result in a neomorphic catalytic activity in cancers. We applied cancer-associated mutations from isocitrate dehydrogenases (IDHs) to homologous residues in the active sites of homoisocitrate dehydrogenases (HIDHs) to derive enzymes that catalyze the conversion of 2-oxoadi...
Autores principales: | Reitman, Zachary J., Choi, Bryan D., Spasojevic, Ivan, Bigner, Darell D., Sampson, John H., Yan, Hai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487689/ https://www.ncbi.nlm.nih.gov/pubmed/23001033 http://dx.doi.org/10.1038/nchembio.1065 |
Ejemplares similares
-
Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012) -
2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP(+)-Dependent Isocitrate Dehydrogenase Mutations
por: Jin, Genglin, et al.
Publicado: (2011) -
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
por: Killela, Patrick J., et al.
Publicado: (2014) -
A novel bispecific antibody recruits T cells to eradicate tumors in the “immunologically privileged” central nervous system
por: Choi, Bryan D., et al.
Publicado: (2013) -
A heterozygous IDH1(R132H/WT) mutation induces genome-wide alterations in DNA methylation
por: Duncan, Christopher G., et al.
Publicado: (2012)